Bios-01. Conditional Survival Analysis in Idh-mutant High-grade Gliomas: an Useful Tool in Clinical Practice
Year: 2025
Type: conference-abstract
Abstract: BACKGROUND The median overall survival of patients with IDH-mutant high-grade gliomas (IDHm HGGs), including grade 3 oligodendroglioma (O3), grade 3 and 4 astrocytoma (A3, A4), is well known. While this information is useful at diagnosis, it fails to account for the evolving prognosis of patients who surpass initial survival expectations. The aim of our study is to estimate the conditional survival of patients with IDHm HGGs enrolled in the French national POLA cohort. MATERIAL AND METHODS We performed a conditional survival analysis to estimate the probability of being alive five additional years given survival at specific timepoints. We also performed a landmark survival analysis to estimate the overall survival in patients free from progression at five years. Results A total of 869 patients were included: 479 O3, 179 A3 and 211 A4. The mOS was 14.9 (95% confidence interval 12.7-NA), 11.3 (9.1-NA) and 5.8 (4.2-7.9) years, respectively. The estimated probability of being alive for an additional 5 years given survival at 1, 5, and 10 years was 83% (79-86%), 79% (74-84%), and 68% (41-84%) for O3; 77% (70-83%), 72% (62-81%), and NA for A3; and 54% (47-61%), 72% (61-80%), and NA for A4. 388 patients (235 O3, 85 A3, 68 A4) who were progression-free 5 years after diagnosis. From the 5-year landmark, their estimated survival probability for an additional 1, 5, and 10 years was 98.3% (96.6-100%), 87.5% (82.9-92.4%), and 74.1% (64.6-85.0%) for O3; 100% (100-100%), 87.5% (79.4-96.5%), and NA for A3; 96.8% (92.9-100%), 81.4% (71.3-92.9%), and NA for A4. Conclusions Conditional survival — defined as the probability of surviving a specified number of additional years given survival to a focus point — provides a useful and hopeful prognostic indicator in IDHm HGGs long-term survivors. These data should be taken into consideration to improve clinical decision-making and patient counseling.
Source: Neuro-Oncology
Authors: Alberto Picca, Lisa Belin, Alice Laurenge, Catherine Carpentier, Olivier Chinot, Elizabeth Cohen-Jonathan Moyal, Apolline Djelad, Charlotte Bronnimann, Mathilde Ducloie, Stefania Cuzzubbo, Carole Gourmelon, Luc Taillandier, Nadia Younan, Carole Ramirez, Luc Bauchet, Elodie Vauleon, Olivier Langlois, Veronique Bourg, Frederic Dhermain, Philippe Menei, Romuald Seizeur, Philippe Colin, Francois Ghiringhelli, Damien Ricard, Elise Deluche, Clothilde Verlut, Thierry Faillot, Mohamed Khettab, Claude Gaultier, Romain Appay, Franck Bielle, Ahmed Idbaih, Emeline Tabouret, Dominique Figarella-Branger, Mehdi Touat, François Ducray, Caroline Dehais
Institutions: Pitié-Salpêtrière Hospital, Institut du Cerveau, Hôpital de la Timone, Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Caen Normandie, Hôpital Saint-Louis, Centre Hospitalier Régional et Universitaire de Nancy, Hôpital Foch, Centre Hospitalier Universitaire de Saint-Étienne, Centre Hospitalier Universitaire de Montpellier, Centre Eugène Marquis, Centre Hospitalier Universitaire de Rouen, Centre Hospitalier Universitaire de Nice, Institut Gustave Roussy, Fondation Gustave Roussy, Centre Hospitalier Universitaire d'Angers, Centre Hospitalier Régional Universitaire de Brest, L’Institut du Cancer Courlancy Reims, Centre Georges François Leclerc, Hôpital d'instruction des Armées Percy, Centre Hospitalier Universitaire de Limoges, Centre Hospitalier Universitaire de Besançon, Hôpital Beaujon, Hopitaux Civils de Colmar
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4416141497
Cites:
Cited by:
Related to: